38 Stock Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
NovoCure Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.65 |
52 Week High | US$78.30 |
52 Week Low | US$10.08 |
Beta | 0.41 |
1 Month Change | 14.83% |
3 Month Change | 36.10% |
1 Year Change | -75.47% |
3 Year Change | -86.20% |
5 Year Change | -65.50% |
Change since IPO | -9.02% |
Recent News & Updates
Recent updates
Shareholder Returns
38 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 11.4% | 2.5% | 0.3% |
1Y | -75.5% | 11.1% | 4.7% |
Return vs Industry: 038 underperformed the German Medical Equipment industry which returned 8.1% over the past year.
Return vs Market: 038 underperformed the German Market which returned 2.1% over the past year.
Price Volatility
38 volatility | |
---|---|
38 Average Weekly Movement | 12.0% |
Medical Equipment Industry Average Movement | 4.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 038's share price has been volatile over the past 3 months.
Volatility Over Time: 038's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 1,453 | Asaf Danziger | https://www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited Fundamentals Summary
38 fundamental statistics | |
---|---|
Market cap | €1.62b |
Earnings (TTM) | -€189.32m |
Revenue (TTM) | €465.74m |
3.5x
P/S Ratio-8.6x
P/E RatioIs 38 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
38 income statement (TTM) | |
---|---|
Revenue | US$509.34m |
Cost of Revenue | US$127.54m |
Gross Profit | US$381.80m |
Other Expenses | US$588.85m |
Earnings | -US$207.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.93 |
Gross Margin | 74.96% |
Net Profit Margin | -40.65% |
Debt/Equity Ratio | 156.9% |
How did 38 perform over the long term?
See historical performance and comparison